Suppr超能文献

预测癌症骨转移患者接受镭-223治疗期间尿8-羟基-2'-脱氧鸟苷水平与骨髓抑制的关系

Predicting bone marrow suppression from urinal 8-hydroxy-2'-deoxyguanosine level during the treatment with radium-223 in patients with cancer bone metastasis.

作者信息

Monzen Satoru, Kasai Yoshihiko, Kinbara Ryota, Suto Katsuhiko, Morino Yuki, Terada Kenji, Wojcik Andrzej, Mariya Yasushi

机构信息

Department of Radiation Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Japan.

Research Center for Biomedical Sciences, Hirosaki University, Hirosaki, Japan.

出版信息

Transl Cancer Res. 2025 Mar 30;14(3):1753-1763. doi: 10.21037/tcr-24-812. Epub 2025 Mar 18.

Abstract

BACKGROUND

Cancer bone metastasis (BM) from castration-resistant prostate cancer (CRPC) is the terminal stage of cancer, and it demonstrates a decreasing quality of life (QOL) due to skeletal-related events such as pain and bone fracture. Radium-223 dichloride administration is frequently selected as an internal radionuclide target therapy. This radioactive molecule has a potency of accumulation in bone minerals and emits alpha particles by decaying radium-223. These physical properties cause cellular damage to bone metastatic CRPC cells. However, some poor outcomes of patients are occasionally observed, such as bone marrow suppression. Therefore, in order to understand the status of deep BM, it is necessary to discover biomarkers that effectively reflect bone metabolism. In this study, we investigated whether urinal 8-hydroxy-2'-deoxyguanosine (8-OHdG), a one of oxidative stress marker, could be a predictive biomarker to identify whether radium-223 administration causes bone marrow suppression in patients.

METHODS

The urine and blood serum from four cancer patients with BM were collected and stored at -80 ℃ deep freezer until analysis. Following radiotherapeutic guidelines, three to six radium-223 internal radiotherapy doses were prescribed based on the patient, and it was terminated due to decreased therapeutic reserve.

RESULTS

The patients who were administered six radium-223 doses demonstrated upregulation of urinal 8-OHdG, serum C-terminal telopeptide of type I collagen (1CTP), and type I collagen cross-linked N-telopeptide (NTX) concentrations. Conversely, serum bone alkaline phosphatase (BAP) was downregulated. The patients who were administered less than five radium-223 doses exhibited urinal 8-OHdG downregulation and similar serum 1CTP, NTX, and BAP levels compared to before administration. In the patient who had bone marrow suppression, a negative correlation between time after first administration of radium-223 and urinal 8-OHdG was observed.

CONCLUSIONS

These results suggest that a urinal 8-OHdG concentration has a potency of biomarker for bone marrow suppression under the administration of radium-223 in the patient with BM from CRPC.

摘要

背景

去势抵抗性前列腺癌(CRPC)的癌症骨转移(BM)是癌症的终末期,由于疼痛和骨折等骨相关事件,患者生活质量(QOL)下降。二氯化镭-223给药常被选为一种内照射放射性核素靶向治疗。这种放射性分子在骨矿物质中有蓄积能力,并通过镭-223衰变发射α粒子。这些物理特性会对骨转移性CRPC细胞造成细胞损伤。然而,偶尔会观察到一些患者预后不佳的情况,如骨髓抑制。因此,为了了解深部BM的状况,有必要发现能有效反映骨代谢的生物标志物。在本研究中,我们调查了作为氧化应激标志物之一的尿8-羟基-2'-脱氧鸟苷(8-OHdG)是否可以作为预测性生物标志物,以识别镭-223给药是否会导致患者骨髓抑制。

方法

收集4例BM癌症患者的尿液和血清,保存在-80℃深冻冰箱中直至分析。按照放射治疗指南,根据患者情况给予三到六次镭-223内照射剂量,因治疗储备下降而终止。

结果

接受六次镭-223剂量给药的患者尿8-OHdG、血清I型胶原C末端肽(1CTP)和I型胶原交联N末端肽(NTX)浓度上调。相反,血清骨碱性磷酸酶(BAP)下调。接受少于五次镭-22

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9382/11985201/2ccb1b929716/tcr-14-03-1753-f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验